Inflammatory bowel disease is a diverse disease that affects people all over the globe. This diversity in setting and treatment options makes it difficult for researchers to estimate the exact cost of ...
Environmental factors like diet and early antibiotic use have an impact on the gut microbiome and can contribute to ...
and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated ...
The other three — Tofidence™ and Tyenne® for Actemra® (tocilizumab) and Pavblu™ for Eylea® (aflibercept) — were the first commercially available biosimilars for their respective ...
and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated ...
Over the past few weeks, the Trump administration has introduced sweeping changes across the federal government that have impacted the federal grantee and contractor community. Adding to these ...
BAT2506, a tumor necrosis factor-alpha (TNF-alpha) blocker, is a Phase 3 biosimilar candidate to Simponi ® (golimumab) Agreement will provide Accord BioPharma with future U.S. commercialization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback